Compare Enveric Biosciences Inc (ENVB) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Match Group Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Match Group Inc trades at $41.48 (market cap $9.37B). The key difference: Match Group Inc is far larger — about 1400.6× Enveric Biosciences Inc's market cap, and Match Group Inc pays a 1.96% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Match Group Inc for 115 Days on average.
| ENVB | MTCH | |
|---|---|---|
Market Cap | $6.69M | $9.37B |
Volume | 41,141 | 2,544,041 |
Sector | Health | Media |
52-Week High | $10.80 | $44.40 |
52-Week Low | $1.27 | $28.90 |
Typical Hold Time | 14 Days | 115 Days |
Enterprise Value | -$1.60M | $12.34B |
Dividend Yield | — | 1.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Match Group (MTCH) trades at $41.50, up 2.17% with a bullish technical outlook. The stock shows strong fundamentals with 74.8% gross margins and consistent earnings beats in recent quarters. Revenue remains stable at $3.5B while net income margin improved to 20.17% in 2025. Analyst consensus is bullish with a $42.29 price target, and institutional activity shows continued interest despite recent selling by some advisors.
MTCH presents a compelling investment case with reasonable valuation (P/E 14.48) and strong cash flow generation. Key risks include high debt levels ($3.85B) and competitive pressures in the dating app market. The company's product innovation and Hinge's growth provide upside potential, though execution risks and market saturation concerns warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
